IFIT3 and cancer: These effects might be explained, at least in part, by the observation that, in this cancer, IFIT1/IFIT3+ T cells mediate immunosuppression in metastatic lymph nodes, thus allowing the propagation of the metastatic disease leading to poorer clinical outcomes [83].